Clinical Trial

A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

Study acronym: FORTITUDE-HCM
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
FORTITUDE-HCM is a global, multicenter, double-blind, parallel-group, placebo-controlled Phase 2b study that will assess the efficacy and safety of ninerafaxstat compared to placebo on top of Standard of Care in patients with symptomatic nHCM
Protocol Amendment History 2 changes
notable Trial sites expanded: 56 -> 67 locations 2026-05-19
notable Trial sites expanded: 23 -> 56 locations 2026-04-28
Trial Details
NCT Number NCT07023614
Lead Sponsor Imbria Pharmaceuticals, Inc.
Conditions Non-obstructive Hypertrophic Cardiomyopathy
Enrollment 165 participants
Start Date 2025-10-06
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-18